{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:26:14Z","timestamp":1789593974545,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["JP25fk0310546"],"award-info":[{"award-number":["JP25fk0310546"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["JP25fk0210163"],"award-info":[{"award-number":["JP25fk0210163"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["JP11AA400168"],"award-info":[{"award-number":["JP11AA400168"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["JP24fk0210106"],"award-info":[{"award-number":["JP24fk0210106"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["JP25fk0210149"],"award-info":[{"award-number":["JP25fk0210149"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["JP23fk0210102"],"award-info":[{"award-number":["JP23fk0210102"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["JP25fk0210136"],"award-info":[{"award-number":["JP25fk0210136"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["JP19cm0106540"],"award-info":[{"award-number":["JP19cm0106540"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008886","name":"Princess Takamatsu Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K02320"],"award-info":[{"award-number":["24K02320"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K27670"],"award-info":[{"award-number":["23K27670"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H01055"],"award-info":[{"award-number":["19H01055"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08864"],"award-info":[{"award-number":["22K08864"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K11997"],"award-info":[{"award-number":["25K11997"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K21627"],"award-info":[{"award-number":["20K21627"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K19554"],"award-info":[{"award-number":["22K19554"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ebiom.2026.106137","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T23:42:22Z","timestamp":1770162142000},"page":"106137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in preclinical mouse models"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6585-3220","authenticated-orcid":false,"given":"Yoshiaki","family":"Tanji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimitsu","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Tsukihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koya","family":"Yasukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kamachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Mochida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ebiom.2026.106137_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106137_bib2","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s10555-020-09924-4","article-title":"Molecular mediators of peritoneal metastasis in pancreatic cancer","volume":"39","author":"Avula","year":"2020","journal-title":"Cancer Metastasis Rev"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106137_bib3","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"O'Reilly","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106137_bib4","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","article-title":"The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma","volume":"13","author":"Renouf","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106137_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/SLA.0000000000004669","article-title":"A phase 3 randomized clinical trial of chemotherapy with or without Algenpantucel-L (HyperAcute-Pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer","volume":"275","author":"Hewitt","year":"2022","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106137_bib6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S1470-2045(14)70236-0","article-title":"Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial","volume":"15","author":"Middleton","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106137_bib7","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106137_bib8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/HEP.0000000000001284","article-title":"Integrative transcriptome profiling elucidates molecular and immunovascular characteristics of macrotrabecular hepatocellular carcinoma","volume":"83","author":"Taniai","year":"2026","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106137_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","article-title":"Molecular subtypes of pancreatic cancer","volume":"16","author":"Collisson","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106137_bib10","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat Med"},{"issue":"7592","key":"10.1016\/j.ebiom.2026.106137_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106137_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13046-023-02935-3","article-title":"Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept","volume":"43","author":"Luo","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106137_bib13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s43018-023-00526-x","article-title":"Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy","volume":"4","author":"B\u00e4rthel","year":"2023","journal-title":"Nat Cancer"},{"issue":"17","key":"10.1016\/j.ebiom.2026.106137_bib14","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1158\/0008-5472.CAN-14-2645","article-title":"Pancreatic cancer cell migration and metastasis is regulated by chemokine-biased agonism and bioenergetic signaling","volume":"75","author":"Roy","year":"2015","journal-title":"Cancer Res"},{"issue":"29","key":"10.1016\/j.ebiom.2026.106137_bib15","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2214320120","article-title":"Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment","volume":"120","author":"Tockary","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106137_bib16","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41467-020-15676-0","article-title":"Adrenergic stress constrains the development of anti-tumor immunity and abscopal responses following local radiation","volume":"11","author":"Chen","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106137_bib17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/ijc.32072","article-title":"Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality","volume":"145","author":"Watanabe","year":"2019","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106137_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106137_bib19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat Immunol"},{"issue":"610","key":"10.1016\/j.ebiom.2026.106137_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc7804","article-title":"Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models","volume":"13","author":"Hotz","year":"2021","journal-title":"Sci Transl Med"},{"issue":"6972","key":"10.1016\/j.ebiom.2026.106137_bib21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106137_bib22","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat Genet"},{"issue":"18","key":"10.1016\/j.ebiom.2026.106137_bib23","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1158\/1078-0432.CCR-17-3401","article-title":"Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic\/predictive significance","volume":"24","author":"Wartenberg","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106137_bib24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/cas.12674","article-title":"Randomized phase II\/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC study","volume":"106","author":"Yamaue","year":"2015","journal-title":"Cancer Sci"},{"issue":"14","key":"10.1016\/j.ebiom.2026.106137_bib25","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1158\/1078-0432.CCR-19-3978","article-title":"Evaluation of Cyclophosphamide\/GVAX pancreas followed by listeria-mesothelin (CRS-207) with or without nivolumab in patients with pancreatic cancer","volume":"26","author":"Tsujikawa","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7963","key":"10.1016\/j.ebiom.2026.106137_bib26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106137_bib27","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(24)00263-8","article-title":"Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study","volume":"25","author":"Van Laethem","year":"2024","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.ebiom.2026.106137_bib28","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-20-0472","article-title":"Intratumoral IL12 mRNA therapy promotes TH1 transformation of the tumor microenvironment","volume":"26","author":"Hewitt","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106137_bib29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ccell.2019.10.006","article-title":"Intratumor adoptive transfer of IL-12 mRNA transiently engineered antitumor CD8(+) T cells","volume":"36","author":"Etxeberria","year":"2019","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106137_bib30","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41565-023-01453-9","article-title":"Close the cancer-immunity cycle by integrating lipid nanoparticle-mRNA formulations and dendritic cell therapy","volume":"18","author":"Zhang","year":"2023","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.ebiom.2026.106137_bib31","article-title":"Intratumoral (IT) MEDI1191 + durvalumab (D): update on the first-in-human study in advanced solid tumors","author":"Casta\u00f1\u00f3n","year":"2023","journal-title":"AACR"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106137_bib32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106137_bib33","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1158\/1078-0432.CCR-18-0381","article-title":"Revisiting interleukin-12 as a cancer immunotherapy agent","volume":"24","author":"Berraondo","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.ebiom.2026.106137_bib34","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1200\/JCO.2002.03.052","article-title":"Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy","volume":"20","author":"Kirkwood","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106137_bib35","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106137_bib36","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","article-title":"mRNA-based cancer therapeutics","volume":"23","author":"Liu","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ebiom.2026.106137_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114993","article-title":"mRNA: a promising platform for cancer immunotherapy","volume":"199","author":"Kong","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ebiom.2026.106137_bib38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.34133\/bmr.0178","article-title":"Current trends in messenger RNA technology for cancer therapeutics","volume":"29","author":"Afzal","year":"2025","journal-title":"Biomater Res"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106137_bib39","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"issue":"26","key":"10.1016\/j.ebiom.2026.106137_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb8133","article-title":"Transient stealth coating of liver sinusoidal wall by anchoring two-armed PEG for retargeting nanomedicines","volume":"6","author":"Dirisala","year":"2020","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106137_bib41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cgh.2020.09.029","article-title":"Interventional endoscopic ultrasound: current status and future directions","volume":"19","author":"DeWitt","year":"2021","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426000186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426000186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:29:24Z","timestamp":1776040164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396426000186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":41,"alternative-id":["S2352396426000186"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106137","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in preclinical mouse models","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106137"}}